Thymmune
Cambridge, US · 2 known investors
Find your way into Thymmune
432 people in our graph share verified history with the Thymmune team — schools, employers, funds. One of them is your warm intro.
Noubar Afeyanunlockedknows Bing Lim · together at Sana Biotechnology (overlapped)
×7knows the team · via Harvard Medical School
×3knows the team · via National Institutes of Health
knows the team · via Wyss Institute for Biologically Inspired Engineering
Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
Founders & leadership
SW
Stan WanginMD, PhDStan Wang holds an MD from Columbia University (via the NIH Medical Scientist Training Program) and a PhD in stem cell biology and regenerative medicine from the University of Cambridge (as a Gates Scholar and NIH-Cambridge Scholar). He was a postdoctoral fellow with George Church at Harvard Medical School and served as Founding Chief Scientific Officer at Cellino Biotech before founding Thymmune Therapeutics, which develops iPSC-derived thymic cell therapies for immunodeficiencies and related disorders.
BL
Bing LiminMD, PhDBing Lim is an MD/PhD physician-scientist with 27 years of research experience at Harvard Medical School and the Genome Institute of Singapore, where his lab developed methods for pluripotent stem cell differentiation and identified markers and therapeutic targets in tumor-initiating cells. He previously held leadership roles in cell therapy and drug discovery at Sana Biotechnology (Senior Vice President) and Merck (Associate Vice President), where he led efforts in stem cell manipulation and translational development, as well as target identification and validation.
MJ
Manish JaininFounder
Investors · 2
Frequently asked questions
- What does Thymmune do?
- Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
- Who founded Thymmune?
- Thymmune was founded by Stan Wang, Bing Lim.
- Who are Thymmune's investors?
- Thymmune's investors include Pillar VC, NYBC Ventures.
- Where is Thymmune headquartered?
- Thymmune is headquartered in Cambridge, US.